Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

The Lancet（2019）

引用 1254|浏览45

暂无评分

摘要

AstraZeneca.

查看译文

关键词

lung cancer,durvalumab,platinum–etoposide,first-line,extensive-stage,small-cell,open-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要